Cardinal Capital Management lessened its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 1.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,721 shares of the company’s stock after selling 1,067 shares during the period. Cardinal Capital Management’s holdings in Sanofi were worth $3,111,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently made changes to their positions in SNY. FMR LLC increased its position in shares of Sanofi by 17.0% in the first quarter. FMR LLC now owns 23,282,201 shares of the company’s stock valued at $1,267,017,000 after buying an additional 3,387,606 shares in the last quarter. Bank of America Corp DE grew its position in Sanofi by 17.0% in the first quarter. Bank of America Corp DE now owns 10,626,939 shares of the company’s stock worth $578,318,000 after acquiring an additional 1,541,832 shares during the period. BlackRock Inc. grew its position in Sanofi by 2.5% in the first quarter. BlackRock Inc. now owns 10,047,856 shares of the company’s stock worth $546,804,000 after acquiring an additional 249,619 shares during the period. Morgan Stanley boosted its stake in Sanofi by 19.3% during the fourth quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock worth $374,513,000 after buying an additional 1,251,199 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Sanofi by 11.9% during the first quarter. Bank of New York Mellon Corp now owns 6,273,931 shares of the company’s stock worth $341,427,000 after buying an additional 667,195 shares during the period. Hedge funds and other institutional investors own 10.06% of the company’s stock.
Sanofi Stock Down 0.8 %
Shares of Sanofi stock opened at $54.08 on Tuesday. Sanofi has a one year low of $36.91 and a one year high of $57.82. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.81 and a current ratio of 1.21. The company has a market cap of $136.54 billion, a P/E ratio of 18.52, a PEG ratio of 1.57 and a beta of 0.57. The firm has a fifty day moving average of $53.22 and a two-hundred day moving average of $53.63.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the stock. HSBC started coverage on shares of Sanofi in a research note on Friday, July 14th. They issued a “buy” rating for the company. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 29th. Finally, Berenberg Bank upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 5th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $72.50.
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
- Five stocks we like better than Sanofi
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
- NYSE Stocks Give Investors a Variety of Quality Options
- Got Nuclear? Three Stocks To Play Energy’s Next Frontier
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- The Top 4 Utilities for Value, Yield, and Upside Potential
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.